The 6th Gene Therapy for CNS Summit is returning to Boston with a refreshed agenda to match exactly with the priorities of the gene therapy field in 2024. With more companies than ever submitting INDs for neurological diseases, preparing for first-in-human trials, and novel capsids proving their worth in positive data readouts showing greater transduction, there’s a clear shift as the innovative promise becomes a reality.

Bringing in-depth content on how novel AAVs are performing in preclinical models, maximizing biodistribution through a variety of administration routes, and applying the significant progress and successes from the first approvals in rare, genetic diseases to more complex, larger patient populations like Alzheimer’s and Parkinson’s.

Join neurology experts who are leveraging gene therapy as the premier modality to tackle neurological disease, across translational, preclinical, R&D, and clinical teams who are dedicating their day-to-day to advance their neurological assets into and through the clinic.

Event link here.